Literature DB >> 22846868

Developments in liver transplantation for hepatocellular carcinoma.

Emmanuel Melloul1, Mickael Lesurtel, Brian I Carr, Pierre-Alain Clavien.   

Abstract

Hepatocellular carcinoma (HCC) is a serious health problem worldwide because of its association with hepatitis B and C viruses. In this setting, liver transplantation (LT) has become one of the best treatments since it removes both the tumor and the underlying liver disease. Due to the improvement of imaging techniques and surveillance programs, HCC are being detected earlier at a stage at which effective treatment is feasible. The prerequisite for long term success of LT for HCC depends on tumor load and strict selection criteria with regard to the size and number of tumor nodules. The need to obtain the optimal benefit from the limited number of organs available has prompted the maintenance of selection criteria in order to list only those patients with early HCC who have a better long-term outcome after LT. The indications for LT and organ allocation system led to many controversies around the use of LT in HCC patients. This review aims at giving the latest updated developments in LT for HCC focusing on selection criteria, diagnostic tools, prognostic factors, treatment on the waiting list, role of living donor liver transplantation and adjuvant therapy, and the impact of immunosuppression on HCC recurrence after LT.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22846868     DOI: 10.1053/j.seminoncol.2012.05.008

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

1.  Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy.

Authors:  Min Yao; Li Wang; Zhizhen Dong; Qi Qian; Yun Shi; Dandan Yu; Shiye Wang; Wenjie Zheng; Dengfu Yao
Journal:  Tumour Biol       Date:  2014-03-16

Review 2.  Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis.

Authors:  Yu Zhang; Zhi-Long Shi; Xia Yang; Zheng-Feng Yin
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Therapeutic actions of melatonin on gastrointestinal cancer development and progression.

Authors:  Rachael Glenister; Kelly McDaniel; Heather Francis; Julie Venter; Kendal Jensen; Giuseppina Dusio; Eugenio Gaudio; Shannon Glaser; Fanyin Meng; Gianfranco Alpini
Journal:  Transl Gastrointest Cancer       Date:  2013-01-01

4.  Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation.

Authors:  Fei Teng; Qiu-Cheng Han; Guo-Shan Ding; Zhi-Jia Ni; Hong Fu; Wen-Yuan Guo; Xiao-Min Shi; Xiao-Gang Gao; Jun Ma; Zhi-Ren Fu
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

Review 5.  Biomarker-based MicroRNA Therapeutic Strategies for Hepatocellular Carcinoma.

Authors:  Min Yao; Li Wang; Yao Yao; Hong-Bing Gu; Deng-Fu Yao
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

6.  Comparison of gene expression in liver regeneration and hepatocellular carcinoma formation.

Authors:  Li Yin; Yahao Wang; Xueqiang Guo; Cunshuan Xu; Guoying Yu
Journal:  Cancer Manag Res       Date:  2018-11-15       Impact factor: 3.989

7.  A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma.

Authors:  Shu-Wen Zhang; Ning-Ning Zhang; Wen-Wen Zhu; Tian Liu; Jia-Yu Lv; Wen-Tao Jiang; Ya-Min Zhang; Tian-Qiang Song; Li Zhang; Yan Xie; Yong-He Zhou; Wei Lu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

8.  Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.

Authors:  Dandan Yu; Zhizhen Dong; Min Yao; Wei Wu; Meijuan Yan; Xiaodi Yan; Liwei Qiu; Jie Chen; Wenli Sai; Dengfu Yao
Journal:  Tumour Biol       Date:  2012-11-29

9.  Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth.

Authors:  Ahmed Lasfar; Andrew de laTorre; Walid Abushahba; Karine A Cohen-Solal; Ismael Castaneda; Yao Yuan; Kenneth Reuhl; Andrew Zloza; Elizabeth Raveche; Debra L Laskin; Sergei V Kotenko
Journal:  Oncotarget       Date:  2016-08-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.